share_log

Viveon Health Acquisition Corp. and Clearday Inc. Announce Signed Letter of Intent to Merge and Create a Leading Longevity Care Company

Viveon Health Acquisition Corp. and Clearday Inc. Announce Signed Letter of Intent to Merge and Create a Leading Longevity Care Company

Viveon Health Acquisition Corp. 和 Clearday Inc. 宣佈簽署合併創建領先的長壽護理公司的意向書
GlobeNewswire ·  2023/03/01 07:08

Healthcare and med-tech management teams join forces to accelerate longevity-tech solutions into more than 130 million American lives by 2030.

到2030年,醫療保健和醫療技術管理團隊聯手將長壽技術解決方案加速進入超過1.3億美國人的生活。

Norcross, Georgia, and San Antonio, Texas, March 01, 2023 (GLOBE NEWSWIRE) -- Viveon Health Acquisition Corp. (NYSE American: VHAQ, VHAQW, VHAQR, VHAQU), a special purpose acquisition company led by principals experienced in healthcare and med-tech innovation, is pleased to announce that it has identified and entered into a letter of intent with a business combination target company, Clearday (OTCQX: CLRD).

喬治亞州諾克羅斯和德克薩斯州聖安東尼奧,2023年3月1日(GLOBE NEWSWIRE)——由醫療保健和醫療技術創新領域經驗豐富的負責人領導的特殊目的收購公司Viveon Health Acquisition Corp(紐約證券交易所美國證券交易所:VHAQ、VHAQU)欣然宣佈,它已確定並與業務合併目標公司Clearday(OTD)簽訂了意向書(OTD CQX: CLRD)。

Clearday provides a technology platform for the aging population that integrates numerous healthcare innovations into personalized, AI-driven care experiences, which continuously assesses an individual's cognitive and physical capabilities.  The company's customized treatment plans are intended to improve the quality of life for aging and special needs populations. With its autonomous companion robotics and innovative care treatments, Clearday intends to address the $1.4 Trillion burden in annual National Health Expenditures for aging adults.   

Clearday 爲老齡化人口提供了一個技術平臺,該平臺將衆多醫療保健創新整合到人工智能驅動的個性化護理體驗中,持續評估個人的認知和身體能力。該公司的定製治療計劃旨在改善老齡化和特殊需求人羣的生活質量。Clearday打算通過其自主伴侶機器人和創新的護理療法,解決老年人每年1.4萬億美元的國民健康支出負擔。

Company Overview

公司概述

Clearday's () mission is to provide industry-leading longevity care that is more accessible and affordable.  Clearday enables aging individuals, those with special needs, and their families, to optimize their quality of life across the healthcare continuum: at home, in community centers, during medical visits, and at full and part-time care facilities. Clearday's Longevity Care Platform seamlessly integrates numerous health technology innovations into personalized AI-driven care experiences.  The platform continuously assesses an individual's cognitive and physical capabilities to deliver a customized plan.

Clearday () 的使命是提供行業領先的、更容易獲得和更實惠的長壽護理。Clearday使老年人、有特殊需要的人及其家庭能夠在整個醫療保健過程中優化他們的生活質量:在家中、在社區中心、就診期間以及在全職和兼職護理機構中。Clearday 的長壽護理平臺將衆多健康技術創新無縫集成到人工智能驅動的個性化護理體驗中。該平臺持續評估個人的認知和身體能力,以提供定製的計劃。

Globally, the population of individuals over the age of 60 is projected to double by 2050, resulting in nearly 2.1 billion people. In 2035, the US Census Bureau predicts that for the first time, there will be more Americans over the age of 65 than those under 18.  These demographics drive the need for new longevity-tech solutions that provide continuous monitoring, increased engagement, and proactive interventions for older individuals.

預計到2050年,全球60歲以上的人口將翻一番,從而達到近21億人。2035年,美國人口普查局預測,65歲以上的美國人將首次超過18歲以下的美國人。這些人口統計數據推動了對新的長壽技術解決方案的需求,這些解決方案爲老年人提供持續監測、提高參與度和積極干預措施。

The Clearday Longevity Care Platform delivers solutions through a hub-n-spoke model involving Clearday at Home, Clearday Labs, Clearday Clubs, Clearday Residential, and Clearday Robotics. Together, they offer the industry's leading proactive engagement, intervention, and monitoring solutions for the aging population.

Clearday 長壽護理平臺通過涉及 Clearday at Home、Clearday Labs、Clearday Clubs、Clearday Residential 和 Clearday Robotics 的中心輻射它們共同爲老齡化人口提供業界領先的主動參與、干預和監測解決方案。

Management Comments

管理層評論

"Clearday is an ideal merger partner for Viveon Health as it is a transformative healthcare technology company at its inflection point of rapid growth — and addresses an underserved, large, and expanding market," said Jagi Gill, Chief Executive Officer and Chairman of Viveon Health. "As operators ourselves in the healthcare technology space, our hands-on diligence revealed the Clearday team's deliberate expansion and acceleration of their longevity-tech business plan impacting the arc from home to residential care facilities. By leveraging its operational excellence and history in longevity care and bolting on AI-driven solutions to monitor mental and physical health, its solutions can deliver real-time engagement with individuals and their families through robotic-assisted companion care designed to deliver support at any setting. I look forward to working with Jim and the rest of the Clearday team to execute their global sales channel expansion and market development plan poised to deliver growth and shareholder value."

Viveon Health首席執行官兼董事長賈吉·吉爾表示:“Clearday是Viveon Health的理想合併合作伙伴,因爲它是一家處於快速增長轉折點的變革性醫療技術公司,其目標是服務不足、龐大且不斷擴大的市場。”“作爲醫療保健技術領域的運營商,我們的親身調查顯示,Clearday團隊刻意擴大和加快了長壽科技業務計劃,影響了從家庭到寄宿護理機構的範圍。通過利用其在長壽護理領域的卓越運營和歷史,並藉助人工智能驅動的解決方案來監測身心健康,其解決方案可以通過專爲在任何環境提供支持的機器人輔助伴侶護理提供與個人及其家庭的實時互動。我期待與吉姆和Clearday團隊的其他成員合作,執行他們的全球銷售渠道擴張和市場發展計劃,以實現增長和股東價值。”

James Walesa, CEO and Founder said, "We are thrilled with the opportunity to partner with Viveon and its industry-leading founders, Drs. Jagi Gill and Rom Papadopoulos. Both have decades of experience scaling healthcare technology businesses. Clearday began seeking partners with operational and financial expertise who shared the vision of Clearday's 'Aging in the Right Place.' It has taken longer than I wanted, but today we found the team that combines capital markets experience with healthcare leadership to accelerate Clearday's mission. Their extensive professional contacts and experience will bolster our sales and go-to-market initiatives and generate additional revenue opportunities for the combined companies."

首席執行官兼創始人詹姆斯·瓦文薩表示:“我們很高興有機會與Viveon及其行業領先的創始人賈吉·吉爾博士和羅姆·帕帕多普洛斯博士合作。兩者都有數十年的擴展醫療技術業務的經驗。Clearday開始尋找具有運營和財務專業知識的合作伙伴,他們與Clearday的 “老齡化在正確的地方” 的願景相同。花了比我想要的更長的時間,但今天我們找到了一支將資本市場經驗與醫療保健領導力相結合的團隊,以加快Clearday的使命。他們廣泛的專業聯繫和經驗將促進我們的銷售和市場進入計劃,併爲合併後的公司創造額外的收入機會。”

Transaction Overview

交易概述

Under the terms of the letter of intent, Clearday's existing equity holders would convert 100% of their equity into the combined public company. The proposed transaction values Clearday at $250 million. Viveon expects to announce additional details regarding the proposed business combination when a definitive merger agreement is executed.

根據意向書的條款,Clearday的現有股權持有人將將其100%的股權轉換爲合併後的上市公司。擬議的交易估值Clearday爲2.5億美元。Viveon預計將在最終合併協議執行時公佈有關擬議業務合併的更多細節。

Completion of a business combination with Clearday is subject to, among other matters, the completion of due diligence, the negotiation of a definitive agreement providing for the transaction, satisfaction of the conditions negotiated therein and approval of the transaction by the board and stockholders of both Viveon and Clearday. There can be no assurance that a definitive agreement will be entered into or that the proposed transaction will be consummated on the terms or timeframe currently contemplated, or at all.

除其他事項外,與Clearday的業務合併的完成取決於盡職調查的完成、規定交易的最終協議的談判、協議中談判的條件的滿足以及Viveon和Clearday董事會和股東對交易的批准。無法保證最終協議會達成,也無法保證擬議的交易將在目前設想的條款或時限內完成,或者根本無法保證。

About Clearday, Inc.

關於 Clearday, Inc.

Clearday is an innovative longevity healthcare technology company with a modern, hopeful vision for making high-quality care solutions more accessible, affordable, and empowering for aging individuals and their families. Clearday has a decades-long experience in non-acute care through its subsidiary Clearday Living, which operates highly-rated residential memory care and adult daycare communities. Its Longevity Care Platform brings Clearday solutions to people wherever they are. Its platform is at the intersection of telehealth, remote monitoring, and patient engagement — all delivered across mobile, wearable, and robotic endpoints in a Software-as-a-Service (SaaS) and Robotics as a Service (RaaS) model. Learn more about Clearday and its pioneering legislative efforts to bring the "Innovative Cognitive Care Act for Veterans" to Congress at .

克利爾迪是一家創新的長壽醫療保健技術公司,其現代而充滿希望的願景是讓老年人及其家庭更容易獲得、負擔得起和增強能力的高質量護理解決方案。Clearday通過其子公司Clearday Living在非急性護理領域擁有數十年的經驗,該公司經營備受好評的寄宿記憶護理和成人日託社區。無論人們身在何處,其長壽護理平臺都能爲他們提供Clearday解決方案。其平臺處於遠程醫療、遠程監控和患者參與的交叉點——所有這些都以軟件即服務 (SaaS) 和機器人即服務 (RaaS) 模式通過移動、可穿戴設備和機器人終端交付。要詳細瞭解Clearday及其爲將 “退伍軍人創新認知保健法案” 提交國會而做出的開創性立法工作,請訪問。

About Viveon Health Acquisition Corp.

關於 Viveon Health 收購公司

Viveon Health Acquisition Corp. is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It is the Company's intention to pursue prospective targets that are focused on the healthcare sector in the United States and other developed countries.

Viveon Health Acquisition Corp. 是一家空白支票公司,通常也被稱爲特殊目的收購公司或SPAC,其成立的目的是與一家或多家企業進行合併、股份交換、資產收購、股份購買、重組或類似的業務合併。該公司打算追求以美國和其他發達國家的醫療保健行業爲重點的預期目標。

No Offer or Solicitation

不得提出要約或邀請

This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

本新聞稿不構成就任何證券或擬議的業務合併徵求委託人、同意或授權。本新聞稿也不構成任何證券的出售要約或徵求購買任何證券的要約,也不得在根據任何此類司法管轄區的證券法進行註冊或資格認證的任何州或司法管轄區出售證券。除非通過符合經修訂的1933年《證券法》第10條要求的招股說明書或該招股說明書的豁免,否則不得發行證券。

Forward-Looking Statements

前瞻性陳述

Certain statements made in this press release are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "target," "believe," "expect," "will," "shall," "may," "anticipate," "estimate," "would," "positioned," "future," "forecast," "intend," "plan," "project," "outlook" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters.  These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations, Viveon's ability to enter into a definitive agreement or consummate a transaction with the target company. These statements are based on various assumptions and on the current expectations of Viveon's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Viveon and the target company. These forward-looking statements are subject to a number of risks and uncertainties, including: Viveon's ability to enter into a definitive agreement with respect to the proposed business combination or consummate a transaction with the target company; the risk that the approval of the stockholders of Viveon for the potential transaction is not obtained; failure to realize the anticipated benefits of the potential transaction, including as a result of a delay in consummating the potential transaction; the amount of redemption requests made by Viveon's stockholders and the amount of funds remaining in Viveon's trust account after satisfaction of such requests; those factors discussed in Viveon's prospectus for its initial public offering dated December 28, 2020, under the heading "Risk Factors," and other documents of Viveon filed, or to be filed, with the SEC. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Viveon presently does not know or that Viveon currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Viveon's expectations, plans or forecasts of future events and views as of the date hereof. Viveon anticipates that subsequent events and developments will cause Viveon's assessments to change. However, while Viveon may elect to update these forward-looking statements at some point in the future, Viveon specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Viveon's assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

本新聞稿中的某些陳述是1995年《私人證券訴訟改革法》“安全港” 條款所指的 “前瞻性陳述”。前瞻性陳述可以通過使用 “目標”、“相信”、“期望”、“將”、“應該”、“可能”、“預期”、“估計”、“將”、“定位”、“未來”、“預測”、“打算”、“計劃”、“項目”、“展望” 等詞語來識別,這些表達方式預測或表明未來事件或趨勢或不是歷史問題陳述。這些前瞻性陳述包括但不限於有關收入的預測、估計和預測以及其他財務和業績指標的陳述,以及對市場機會和預期的預測,Viveon與目標公司簽訂最終協議或完成交易的能力。這些陳述基於各種假設和Viveon管理層當前的預期,而不是對實際業績的預測。這些前瞻性陳述僅用於說明目的,無意用作擔保、保證、預測或明確的事實或概率陳述,也不得被任何投資者作爲擔保、保證、預測或明確的事實或概率陳述。實際事件和情況很難或不可能預測,並且會與假設有所不同。許多實際事件和情況是Viveon和目標公司無法控制的。這些前瞻性陳述受許多風險和不確定性的影響,包括:Viveon能否就擬議的業務合併達成最終協議或與目標公司完成交易;潛在交易未獲得Viveon股東批准的風險;未能實現潛在交易的預期收益,包括潛在交易延遲完成所致;贖回申請金額由 Viveon 的股東製作以及滿足此類請求後Viveon信託賬戶中剩餘的資金金額;Viveon在2020年12月28日標題爲 “風險因素” 的首次公開募股招股說明書以及Viveon向美國證券交易委員會提交或將要提交的其他文件中討論的因素。如果風險出現或假設被證明不正確,則實際結果可能與這些前瞻性陳述所暗示的結果存在重大差異。可能還有其他風險是Viveon目前不知道的,或者是Viveon目前認爲不重要的風險,這些風險也可能導致實際結果與前瞻性陳述中包含的結果不同。此外,前瞻性陳述反映了截至本文發佈之日Viveon對未來事件和觀點的預期、計劃或預測。Viveon預計,隨後的事件和事態發展將導致Viveon的評估發生變化。但是,儘管Viveon可能會選擇在未來的某個時候更新這些前瞻性陳述,但Viveon明確表示不承擔任何這樣做的義務。截至本新聞稿發佈之日之後的任何日期,均不應依賴這些前瞻性陳述來代表Viveon的評估。因此,不應過分依賴前瞻性陳述。

Contact:

聯繫人:

Rom Papadopoulos
Viveon Health Acquisition Corp.
Chief Financial Officer
rom@viveonhealth.com
404-861-0839

羅姆·帕帕多普洛斯
Viveon Health 收購公司
首席財務官
rom@viveonhealth.com
404-861-0839

Ginny Connolly
Clearday Inc.
Investor Relations
info@myclearday.com
210-451-0839

金妮康諾利
Clearday Inc.
投資者關係
info@myclearday.com
210-451-0839


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論